New therapies for castrate-resistant prostate cancer

被引：3

作者：

Williams, Stephen B. ^{[1
]}

Lay, Aaron H. ^{[1
]}

Lau, Clayton S. ^{[2
]}

Josephson, David Y. ^{[2
]}

Wilson, Timothy G. ^{[2
]}

Choueiri, Toni K. ^{[3
]}

Pal, Sumanta K. ^{[4
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Div Urol, Sch Med, Boston, MA 02115 USA

[2] City Hope Comprehens Canc Ctr, Div Urol Oncol, Dept Urol, Duarte, CA 91010 USA

[3] Harvard Univ, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA

[4] City Hope Comprehens Canc Ctr, Div Genitourinary Malignancies, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 13期

关键词：

castrate resistant; chemotherapy; outcomes; prostate cancer; review; MITOXANTRONE PLUS PREDNISONE; I CLINICAL-TRIAL; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; DOCETAXEL; CYP17; INHIBITOR; IMMUNOTHERAPY; ANTIANDROGEN; CHEMOTHERAPY;

D O I：

10.1517/14656566.2011.590133

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

引用

页码：2069 / 2074

页数：6

共 50 条

[41] New treatment options for castrate-resistant prostate cancer: a urology perspective
Gomella, Leonard G.
Gelpi, Francisco
Kelly, William Kevin
[J]. CANADIAN JOURNAL OF UROLOGY, 2011, 18 (04) : 5767 - 5777
[42] Metastatic castrate-resistant prostate cancer, dawn of a new age of management
Nemr, Elie G.
[J]. BJU INTERNATIONAL, 2013, 111 (03) : E9 - E10
[43] Towards a new era in care for metastatic castrate-resistant prostate cancer
Mason, Malcolm
[J]. JOURNAL OF CLINICAL UROLOGY, 2011, 4 (01) : S1 - S1
[44] Current clinical trials in castrate-resistant prostate cancer
Petrylak D.P.
[J]. Current Urology Reports, 2011, 12 (3) : 173 - 179
[45] Future Directions in Castrate-Resistant Prostate Cancer Therapy
Antonarakis, Emmanuel S.
Carducci, Michael A.
[J]. CLINICAL GENITOURINARY CANCER, 2010, 8 (01) : 37 - 46
[46] Treatment sequencing in metastatic castrate-resistant prostate cancer
Sartor, Oliver
Gillessen, Silke
[J]. ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431
[47] New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer
Lawrence, Mitchell
Clouston, David
Frydenberg, Mark
Murphy, Declan G.
Pezaro, Carmel Jo
Pook, David William
Thorne, Heather
Sandhu, Shahneen Kaur
Toivanen, Roxanne
Taylor, Renea
Risbridger, Gail
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[48] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Beckett, Robert D.
Rodeffer, Kathryn M.
Snodgrass, Rachel
[J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
[49] Symptom Clusters in Men With Castrate-Resistant Prostate Cancer
Vayne-Bossert, Petra
Hardy, Janet
Skerman, Helen
Yates, Patsy
Sullivan, Karyn
Good, Phillip
[J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2017, 54 (03) : E1 - E3
[50] Incidence of dural metastases in castrate-resistant prostate cancer
Khondker, Adree
Kwong, Jethro C. C.
Tran, Christopher
Evans, Emily
Aditya, Ishan
Raveendran, Lucshman
Chen, Yingming A.
Ali, Amna
Feifer, Andrew
[J]. JOURNAL OF CLINICAL UROLOGY, 2024, 17 (04) : 378 - 385

← 1 2 3 4 5 →